Combined RAF (dabrafenib) and MEK (trametinib) inhibition was shown to effectively lower MAPK signaling and yielded a 64% response rate in non-small-cell lung cancer (NSCLC) patients. …

2019年7月1日 · From a therapeutic point of view, we cannot drive any definitive conclusion on anti-EGFR sensitivity of BRAF class 2 and 3 patients. A recent case report described a class 2 …

BRAF突变 是多个 实体瘤 的重要治疗靶点之一，其在 黑色素瘤 、甲状腺癌、结直肠癌和NSCLC中的突变率不一。 针对不同瘤种的BRAF突变患者，目前分别获批了不同的 靶向治疗药物。 如 …

Importantly, emerging evidence has recently indicated that new types of mutations (classes II and III) also play a paramount role in the development of cancer. In this minireview, we discuss the …

2023年1月25日 · BRAF non-V600 mutants can be further classified as RAS-independent active dimers (Class2) and RAS-dependent impaired kinase (Class3). We retrospectively reviewed …

2018年3月15日 · Class I BRAF mutations affect amino acid V600 and signal as RAS-independent active monomers, class II mutations function as RAS-independent activated dimers, and class …

2019年9月17日 · However, 50-80% of BRAF mutations in lung cancer are non-V600, and can be class II, with intermediate to high kinase activity and RAS independence, or class III, with …

2022年1月4日 · In an elegant experiment, the authors microinjected a RAS-neutralizing mAb into BRAF mutant and wild-type cancer cell lines to inhibit RAS signaling, finding that proliferation …

2019年7月1日 · A higher median CD3/CD8-positive lymphocyte infiltration was observed in BRAF-mutated class 2 (P = 0.033) compared with class 3 cases. Conclusions: For the first …

2022年6月2日 · BRAF mutations, present in 2%-5%, have emerged as therapeutic targets, and can be divided into three classes: kinase-activating monomers (class I, V600) or dimers (class …